Place your bets - end 2019, page-8

I think Matt is keeping a lot of things close to his chest, namely the antiseptic product. To be as effective if not better than Bactroban is supurb, but it is early days. I await a more highly concentrated topical formula for the potential treatment of melanomas or other such skin lesions. Don't think for a second they haven't thought of it. But reality is different to dreams and we progress. Phase 1b sore eye assist results are imminent and I expect good stuff. Our little company still has a lot of catching up to do in terms of SP but many of us are quite confident. Novelty in the dermal space has been a long time coming and we are definitely in the mix. I just wish that the European chief medical officer has some seriously good data to report on and get us out there. Enjoy the weekend and crack a good BOT and toast to 2019.